Physician profile
Abdul Qadir
NPI 1902809742
$4,085.14
in general payments reported to CMS, 2019-2025
38 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $337 · 2021: $734 · 2022: $720 · 2023: $627 · 2024: $709 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $446.68 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $367.14 | 2019-2024 | Xtampza, Belbuca |
| Novo Nordisk INC | $338.63 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.72 | 2021-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $311.50 | 2021-2023 | |
| Abbvie INC. | $226.74 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $222.62 | 2019-2025 | Farxiga, Breztri |
| Smith+Nephew, INC. | $198.85 | 2019-2025 | Collagenase Santyl |
| Lilly USA, LLC | $154.04 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $149.78 | 2022-2025 | |
| Glaxosmithkline, LLC. | $135.39 | 2019-2024 | Arexvy |
| Phathom Pharmaceuticals, INC. | $129.04 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $105.79 | 2019 | |
| Si-Bone, INC. | $104.60 | 2023-2024 | |
| Pfizer INC. | $101.96 | 2019-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $98.37 | 2019 | |
| Mdd US Operations, LLC | $93.17 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $65.39 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $60.20 | 2019-2023 | Ajovy, Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $59.17 | 2022-2023 | Seglentis |
| Redhill Biopharma INC. | $41.29 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $39.77 | 2020-2022 | |
| Daiichi Sankyo INC. | $37.64 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $33.11 | 2024-2025 | Rexulti |
| Dexcom, INC. | $26.90 | 2021 | |
| Uswm, LLC | $24.35 | 2021 | |
| Exact Sciences Corporation | $21.18 | 2025 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Biogen, INC. | $17.33 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.28 | 2021 | |
| Averitas Pharma INC. | $15.43 | 2023 | Qutenza |
| Lundbeck LLC | $14.50 | 2025 | Rexulti |
| Indivior INC. | $13.86 | 2020 | |
| Grt US Holding, INC. | $13.83 | 2021 | |
| Merck Sharp & Dohme LLC | $13.61 | 2021 | |
| Sanofi Pasteur INC. | $12.72 | 2019 | |
| Abbott Laboratories | $11.82 | 2021 | |
| Medtronic Vascular, INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Qadir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.